News

Categories

September 12, 2022

Zymeworks Reports Preliminary Phase 1 Trial Results For Zanidatamab Zovodotin (ZW49) At European Society For Medical Oncology Annual Congress

September 4, 2022

Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers

August 4, 2022

Zymeworks Provides Corporate Update And Reports Second Quarter 2022 Financial Results

August 1, 2022

Zymeworks Announces Participation In Upcoming Investor Conferences

July 25, 2022

Zymeworks Announces Oral Presentation Of Data From Phase 1 Study Of Zanidatamab Zovodotin (ZW49) In Solid Cancers At European Society For Medical Oncology (ESMO) Congress 2022 In Paris

July 21, 2022

Zymeworks To Host Second Quarter Results Conference Call

July 11, 2022

Zymeworks Statement on U.S. Supreme Court Overturning Roe v. Wade

June 27, 2022

Zymeworks Appoints Dr. Paul Moore As Chief Scientific Officer

May 27, 2022

Zymeworks Announces Participation In Upcoming Investor Conference

May 26, 2022

Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022

May 18, 2022

Zymeworks to Present Trials in Progress Poster for HERIZON-GEA-01 at ESMO GI

May 2, 2022

Zymeworks Announces Participation In Upcoming Investor Conferences